# US 2023/0406928 A1 · Methods of treating neuromyelitis optica spectrum disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406928 A1
- Document ID: US20230406928A1
- Status: Published application
- Kind: A1
- Application number: 18/147,287
- Filed: 2022-12-28
- Published: 2023-12-21
- Earliest claimed: 2020-06-30
- Assignees: Viela Bio, Inc.
- Applicants: Viela Bio, Inc.
- Inventors: William REES; Eliezer KATZ; Michael SMITH; Nanette MITTEREDER
- Web page: https://patentgrep.com/patent/US20230406928A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating neuromyelitis optica spectrum disorder (NMOSD) are disclosed herein. In particular, methods of treating NMOSD in a subject identified as having a higher or lower level of NMOSD-disease activity, e.g., by serum glial fibrillary acidic protein concentration, are provided.

## Claims

### Claim at position 1

1-59. (canceled)

### Claim 60

A method of treating neuromyelitis optica spectrum disorder (NMOSD) in a subject in need thereof, the method comprising administering a therapeutically effective amount of a B cell depleting therapy to the subject in need thereof, wherein a sample of the subject has an elevated glial fibrillary acidic protein (GFAP) concentration.

### Claim 61 (depends on 60)

The method of claim 60, wherein the elevated GFAP concentration is ≥2 standard deviations above a healthy donor mean concentration.

### Claim 62 (depends on 60)

The method of claim 60, wherein the elevated GFAP concentration is at least about 170 pg/mL.

### Claim 63 (depends on 60)

The method of claim 60, wherein the administration reduces: (a) a number of NMOSD-related attacks in the subject in need thereof after the administering as compared to a baseline number of NMOSD-related attacks in the subject in need thereof before the administering; or (b) a number of NMOSD-related attacks in the subject in need thereof after the administering as compared to an otherwise comparable control subject lacking the administering.

### Claim 64 (depends on 60)

The method of claim 60, wherein the administration is effective at reducing: (a) a number of magnetic resonance imaging (MRI) lesions; (b) a rate of increase in new MRI lesions; or (c) both (a) and (b).

### Claim 65 (depends on 60)

The method of claim 60, wherein the administration is effective at: (a) reducing a rate of worsening of expanded disability status scale (EDSS) score; or b) improving the EDSS score.

### Claim 66 (depends on 60)

The method of claim 60, wherein the administration is effective at preventing NMOSD relapse in the subject as determined by: (a) a reduction in a number of MRI lesions; (b) a reduction in size of MRI lesions; or (c) both (a) and (b).

### Claim 67 (depends on 60)

The method of claim 60, wherein the administration is effective at suppressing an NMOSD-related attack in the subject.

### Claim 68 (depends on 67)

The method of claim 67, wherein the subject is administered a second therapeutic selected from the group consisting of: a steroid, plasmapheresis, immunoadsorption, and a complement inhibitor.

### Claim 69 (depends on 67)

The method of claim 67, wherein the subject is administered a second therapeutic selected from the group consisting of: Eculizumab, Satralizumab, Ublituximab, Ravulizumab, Rituximab, Azathioprine, Mycophenolate Mofetil, a low dose corticosteroid, and any combination thereof.

### Claim 70 (depends on 60)

The method of claim 60, wherein the B cell depleting therapy is selected from the group consisting of an: anti-CD19 antibody, anti-CD20 antibody, and an anti-CD22 antibody.

### Claim 71 (depends on 70)

The method of claim 70, wherein the B cell depleting therapy is the anti-CD19 antibody.

### Claim 72 (depends on 71)

The method of claim 71, wherein the anti-CD19 antibody comprises Inebilizumab.

### Claim 73 (depends on 72)

The method of claim 72, wherein the Inebilizumab is administered at a dose of 300 mg.

### Claim 74 (depends on 60)

The method of claim 60, wherein the administration is repeated every six months.

### Claim 75

A method of treating neuromyelitis optica spectrum disorder (NMOSD) in a subject in need thereof, the method comprising administering a therapeutically effective amount of Inebilizumab to the subject in need thereof, wherein a serum sample of the subject has an elevated concentration of a biomarker selected from the group consisting of: glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), and TAU.

### Claim 76 (depends on 75)

The method of claim 75, wherein the biomarker is GFAP.

### Claim 77 (depends on 75)

The method of claim 75, wherein the biomarker is TAU.

### Claim 78 (depends on 75)

The method of claim 75, wherein the biomarker is UCHL1.

### Claim 79 (depends on 75)

The method of claim 75, wherein the biomarker is NfL.

### Claim 80 (depends on 75)

The method of claim 75, wherein the administering comprises 300 mg of Inebilizumab administered every six months.

### Claim 81 (depends on 75)

The method of claim 75, wherein prior to the administration, the subject is selected as comprising the elevated concentration of the biomarker.

### Claim 82 (depends on 75)

The method of claim 75, wherein the administration is effective at reducing: (a) a number of NMOSD-related attacks in the subject in need thereof after the administering as compared to a baseline number of NMOSD-related attacks in the subject in need thereof before the administering; or (b) a number of NMOSD-related attacks in the subject in need thereof after the administering as compared to an otherwise comparable control subject lacking the administering.

### Claim 83 (depends on 75)

The method of claim 75, wherein the administration is effective at reducing: (a) a number of magnetic resonance imaging (MRI) lesions; (b) a rate of increase in new MRI lesions; or (c) both (a) and (b).

### Claim 84 (depends on 75)

The method of claim 75, wherein the administration is effective at: (a) reducing a rate of worsening of expanded disability status scale (EDSS) score; or b) improving the EDSS score.

### Claim 85 (depends on 75)

The method of claim 75, wherein the administration is effective at preventing NMOSD relapse in the subject as determined by: (a) a reduction in a number of MRI lesions; (b) a reduction in size of MRI lesions; or (c) both (a) and (b).

### Claim 86 (depends on 75)

The method of claim 75, wherein the administration is effective at suppressing an NMOSD-related attack in the subject.

### Claim 87 (depends on 76)

The method of claim 76, wherein the elevated GFAP concentration is ≥2 standard deviations above a healthy donor mean concentration.

### Claim 88 (depends on 75)

The method of claim 75, wherein the serum sample is positive for all of GFAP, NfL, UCH-L1, and TAU.

### Claim 89

A method of treating neuromyelitis optica spectrum disorder (NMOSD) in a subject in need thereof, the method comprising administering Inebilizumab to a subject in need, wherein a sample of the subject is determined to have an elevated concentration of a biomarker of neuronal injury.

### Claim 90 (depends on 89)

The method of claim 89, wherein the biomarker of neuronal injury is selected from the group consisting of: glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), and TAU.
